SCHEDULE 13G/A: EcoR1 Capital and Oleg Nodelman Disclose 1.4% Stake in Aadi Bioscience

EcoR1 Capital, LLC and its control person Oleg Nodelman, along with EcoR1 Capital Fund Qualified, L.P., have filed an amended Schedule 13G disclosing their beneficial ownership of 1.4% of Aadi Bioscience, Inc.'s common stock as of December 31, 2024.

Summary

• EcoR1 Capital, LLC, Oleg Nodelman, and EcoR1 Capital Fund Qualified, L.P. jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Aadi Bioscience, Inc.
• As of December 31, 2024, EcoR1 Capital, LLC and Oleg Nodelman each beneficially owned 345,253 shares of Aadi Bioscience, Inc. Common Stock, representing 1.4% of the class.
• EcoR1 Capital Fund Qualified, L.P. beneficially owned 324,365 shares, representing 1.3% of the class.
• The percentages are calculated based on 24,647,392 shares of Common Stock outstanding on November 1, 2024, as reported in Aadi Bioscience's Form 10-Q for the quarter ended September 30, 2024.
• EcoR1 Capital, LLC serves as the general partner and investment adviser for investment funds, including Qualified Fund, and Oleg Nodelman is the control person of EcoR1 Capital, LLC.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 5

Explanation: This is a factual disclosure of beneficial ownership, which is neutral in sentiment. It does not contain performance data, forward-looking statements, or strategic updates that would typically influence sentiment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership stakes, which can influence investor perception and trading activity.

Key Dates

Keywords

Aadi Bioscience, EcoR1 Capital, Oleg Nodelman, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Investor, Biotechnology